Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF Plus Chemoradiotherapy in Newly Diagnosed Glioblastoma
NCT04443010Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Jan 2021
- Primary completion
- Oct 2026
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of onfekafusp alfa in glioblastoma (GBM), sponsored by Philogen. Started Jan 2021; status: recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04443010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443010.